Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody ,,therapeutics

Contact: Kurt Leutzinger Vice President and Chief Financial Officer Abgenix Inc. (510) 608-6575 and Marion E. Glick Porter Novelli 212/601-8273 Arthur Mandell Senior Vice President, Corporate and Business Development Human Genome Sciences 301/309-8504 and Kate de Santis Director, Corporate Communications and Investor Relations Human Genome Sciences 301/251-6003 HUMAN GENOME SCIENCES AND ABGENIX ENTER A BROAD COLLABORATION TO CREATE FULLY HUMAN ANTIBODY THERAPEUTICS ROCKVILLE, MARYLAND and FREMONT, CALIFORNIA-- December 1, 1999 -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Abgenix, Inc. (Nasdaq: ABGX) announced today a broad collaboration and technology exchange to identify dozens of novel human antibody drug candidates for development and commercialization. Under this multi-year agreement, HGS has the right to use Abgenix's XenoMouse (TM) technology to generate fully human antibody drug candidates using HGS' proprietary novel targets. HGS has identified and characterized thousands of fully-cloned expressed secretory proteins that provide a source of novel antigens. HGS will develop and commercialize independently antibody-based drugs arising from this collaboration. Abgenix also has an option in the future to develop and commercialize independently products derived from HGS antigens. HGS and Abgenix will pay reciprocal milestones and royalties for products developed and commercialized. In addition, the two companies will work together on certain antigens applying their complementary expertise to jointly develop additional antibody drugs. Abgenix and HGS intend to select up to two targets of interest each year for shared development and commercialization. Both Abgenix and HGS have built a product development capability in recent years. Abgenix has multiple proprietary antibody product candidates under development internally and is conducting three clinical trial programs for graft-versus-host disease,

Contact: Kurt Leutzinger, Abgenix, Inc.
Porter Novelli

Page: 1 2 3 4

Related biology news :

1. Human chromosome 5 final sequence analysis released to public
2. Humans march to a faster genetic drummer than primates, UC Riverside research says
3. Applied Mathematical Models in Human Physiology
4. Human health risks in space flight focus of research internships
5. Human periodontal ligament stem cells isolated for the first time
6. Organization for Human Brain Mapping 2004 Annual Meeting
7. 20 May AAAS lecture: Computers that Respond to Human Emotion
8. Human brain works heavy statistics learning language
9. New Woods Hole Center for Oceans and Human Health established
10. European Society of Human Reproduction and Embryology conference - June 2004
11. Human genome-wide RNAi library for biotech and pharma research

Post Your Comments:

(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
(Date:6/23/2020)... ... , ... The field of quantitation of large molecules or proteins has been ... However, the use of mass spectrometry in this field has gained a lot of ... you choose which approach to use (LBA or MS)?” In many cases, either ...
(Date:6/19/2020)... ... , ... The director of stem cell biotechnology company Asymmetrex , Dr. ... pharmaceutical industries have easier access to stem cell counting, they will soon make it ... Independence Day weekend in the U.S., Asymmetrex is offering free tissue stem cell counting ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... Introducing Ardent ... for transformative growth, , Known as MediVet Biologics since its ... , The new Ardent Animal Health will build on its base of ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... they have entered into a strategic partnership whereby Catalent will provide support for ...
(Date:7/18/2020)... , ... July 16, 2020 , ... After research model ... completion of a great surgery is only the beginning of a successful study, while ... community. , Join Brad Gien, Global Head of Surgery from Envigo in ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Institute of Technology (MIT) has expanded the company’s exclusive license to include ... into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. ...
Breaking Biology Technology:
Cached News: